Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | CSF1R | P07333 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769231 | 0.82 | MAPK10 (0.49) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL2771305 | 0.81 | MAPK8 (0.57) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL2768004 | 0.79 | MAPK8 (0.52) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL2769394 | 0.78 | MAPK10 (0.76) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL2768727 | 0.76 | MAPK8 (0.52) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL2769382 | 0.73 | NPC1 (0.44) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL2769418 | 0.73 | ABL1 (0.46) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL2768161 | 0.72 | KDR (0.50) | MAPK10MAPK8MAPK9CHEK1KDR | |
| SCHEMBL11000829 | 0.72 | PNMT (0.47) | NPC1DYRK1AKDM4EALDH1A1RAB9A | |
| SCHEMBL2771632 | 0.72 | MAPK8 (0.44) | MAPK10MAPK8MAPK9CHEK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060111419-A1 | Novel fused indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1479670-A1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111419-A1 | Novel fused indazole compounds | MAP2K3, MAP3K11, MAP2K2 | MAPK10 39/4885MAPK8 38/4885MAPK9 42/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | MAPK10 12/4885MAPK8 25/4885MAPK9 1/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | MAPK10 12/4885MAPK8 25/4885MAPK9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.